Multiple Sclerosis, Chronic Progressive: all 244 studies

Page 1 of 3. Open to participants first (53), then studies with results posted, then the rest; newest registration first within each.

• REAL-MS: Observational Database Study of AHSCT and MS TherapiesRecruitingNCT07899502
• A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)RecruitingNCT07840326Phase 2
• Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.Not yet recruitingNCT07831928Not applicable
• C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard TherapyNot yet recruitingNCT07825389Phase 1/2
• A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune DiseaseNot yet recruitingNCT07804004Phase 1/2
• A Basket Study of CTA313 in Participants With Active Autoimmune DiseasesNot yet recruitingNCT07783269Phase 1
• Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)Not yet recruitingNCT07765212Phase 2
• Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple SclerosisNot yet recruitingNCT07756268Phase 1/2
• MS-Related Disability Worsening and Thalamic Volume LossEnrolling by invitationNCT07753928
• Acute Intermittent Hypoxia Combined With Gait Training in Multiple SclerosisNot yet recruitingNCT07631923Not applicable
• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyRecruitingNCT07609719Phase 4
• Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple SclerosisRecruitingNCT07587125Phase 1
• Treatment of Participants With Primary or Secondary Progressive Multiple SclerosisRecruitingNCT07477639Phase 1/2
• Cognitive Performance, Sleep Disturbances and Fatigue in Multiple SclerosisRecruitingNCT07426991
• Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) PatientsRecruitingNCT07392879Not applicable
• Home Based Functional Balance Intervention for Multiple SclerosisRecruitingNCT07355387Not applicable
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisRecruitingNCT07299019Phase 3
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)RecruitingNCT07282574Phase 2
• Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health CareNot yet recruitingNCT07280871
• Senolytics for Secondary Progressive MSNot yet recruitingNCT07270120Phase 1
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruitingNCT07225504Phase 3
• A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MSNot yet recruitingNCT07222956Phase 2
• "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MSRecruitingNCT07222618
• Obe-cel in Refractory Progressive Forms of Multiple SclerosisRecruitingNCT07139743Phase 1
• Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune DiseasesRecruitingNCT07085676Phase 1
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruitingNCT07067463Phase 3
• Study of NG01 Cell Therapy in Secondary Progressive Multiple SclerosisNot yet recruitingNCT06961383Phase 2
• A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple SclerosisNot yet recruitingNCT06900192Phase 1
• The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple SclerosisRecruitingNCT06599307Phase 2
• Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)RecruitingNCT06526364
• Development of Camera Based Gait Quality Measure for Persons With Multiple SclerosisRecruitingNCT06516458
• Telerehabilitation in Progressive Multiple SclerosisNot yet recruitingNCT06485115Not applicable
• Effects of Acute Intermittent Hypoxia on Neuroplasticity in MSRecruitingNCT06390930Not applicable
• Intermittent Hypoxia in Persons With Multiple SclerosisRecruitingNCT06276634Not applicable
• Study of Circadian Focused Light Therapy in Progressive Multiple SclerosisEnrolling by invitationNCT06261528Phase 1
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple SclerosisRecruitingNCT06138132Phase 1
• Impact of the Cionic Neural Sleeve on Mobility in Multiple SclerosisRecruitingNCT05964829Not applicable
• Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).RecruitingNCT05961644Phase 2/3
• Osmotin Plant Protein for Progressive Multiple SclerosisRecruitingNCT05937802Not applicable
• Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple SclerosisRecruitingNCT05811013Not applicable
• Nicotinamide Riboside Supplementation In Progressive Multiple SclerosisRecruitingNCT05740722Phase 2
• Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple SclerosisEnrolling by invitationNCT05706220
• Multiple Sclerosis Prediction and Monitoring of Progression StudyRecruitingNCT05685784Not applicable
• Exercise Effects in Multiple SclerosisRecruitingNCT05496881Not applicable
• Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair TherapyRecruitingNCT05359653Phase 1/2
• MS-ResearchBiomarkerSRecruitingNCT05204459
• Imaging the Interplay Between Axonal Damage and Repair in Multiple SclerosisRecruitingNCT05177523
• Gray Matter Demyelination in Primary Progressive MS at 7TRecruitingNCT04977622
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)RecruitingNCT04047628Phase 3
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple SclerosisRecruitingNCT03783416Phase 1
• Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714RecruitingNCT03691077Phase 3
• Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)RecruitingNCT03109288Phase 1/2
• Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)RecruitingNCT02903537Phase 1
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple SclerosisCompletedNCT05232825Phase 3Results posted
• Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple SclerosisTerminatedNCT04925557Phase 2/3Results posted
• Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)CompletedNCT04792567Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)Active, not recruitingNCT04548999Phase 3Results posted
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)CompletedNCT04411641Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisActive, not recruitingNCT04035005Phase 3Results posted
• G-EO Gait Rehabilitation Training in Progressive Multiple SclerosisCompletedNCT03980145Not applicableResults posted
• Simvastatin in Secondary Progressive Multiple SclerosisCompletedNCT03896217Phase 2Results posted
• Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSCompletedNCT03799718Phase 2Results posted
• A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple SclerosisCompletedNCT03737812Phase 2Results posted
• Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With OcrevusCompletedNCT03562975Results posted
• A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS PatientsCompletedNCT03560739Phase 2Results posted
• A Trial of Bile Acid Supplementation in Patients With Multiple SclerosisCompletedNCT03423121Phase 1/2Results posted
• Lipoic Acid for Progressive Multiple Sclerosis (MS)CompletedNCT03161028Phase 2Results posted
• Intranasal Insulin for Improving Cognitive Function in Multiple SclerosisCompletedNCT02988401Phase 1/2Results posted
• Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)TerminatedNCT02936037Phase 3Results posted
• A Study of Oxidative Pathways in MS FatigueCompletedNCT02804594Phase 2Results posted
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)CompletedNCT02688985Phase 3Results posted
• BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisTerminatedNCT02430532Phase 3Results posted
• Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple SclerosisTerminatedNCT02296346Not applicableResults posted
• Effects of Acthar on Recovery From Cognitive Relapses in MSCompletedNCT02290444Phase 3Results posted
• A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboCompletedNCT02284568Phase 2Results posted
• A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MSCompletedNCT02208050Phase 4Results posted
• Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisCompletedNCT01982942Phase 2Results posted
• ACTH in Progressive Forms of MSTerminatedNCT01950234Phase 2Results posted
• Idebenone for Primary Progressive Multiple SclerosisCompletedNCT01854359Phase 1/2Results posted
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)CompletedNCT01665144Phase 3Results posted
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3Results posted
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisCompletedNCT01194570Phase 3Results posted
• Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)CompletedNCT01188811Phase 2/3Results posted
• Patient Research Cohort: Rapidly Evolving Multiple SclerosisCompletedNCT01044576Results posted
• Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)CompletedNCT00950248Phase 1/2Results posted
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.TerminatedNCT00731692Phase 3Results posted
• Investigation of Simvastatin in Secondary Progressive Multiple SclerosisCompletedNCT00647348Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple SclerosisCompletedNCT00087529Phase 2/3Results posted
• Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple SclerosisCompletedNCT07680738Not applicable
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisActive, not recruitingNCT07667322Phase 1
• A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune DiseasesWithdrawnNCT07583030Early Phase 1
• The Effects of a 12-week In-phase Bilateral Exercise Programme on the Corticospinal Plasticity in People With Progressive Multiple SclerosisCompletedNCT07548242Not applicable
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisActive, not recruitingNCT07483450Phase 4
• Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT07235644
• A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in RussiaCompletedNCT07168694
• RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple SclerosisWithdrawnNCT07006805Phase 1/2
• Cladribine Tablets as an Exit Therapy StrategyCompletedNCT06887426
• Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple SclerosisWithdrawnNCT06841068Phase 1/2
• Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical PracticeCompletedNCT06737419

← Multiple Sclerosis, Chronic Progressive overview